Maddalena Delma Caiati's questions to argenx SE (ARGX) leadership • Q4 2024
Question
Maddalena Delma Caiati, on for Yatin Suneja, asked about the dosing regimen in the seronegative and ocular MG trials, whether these patients might require more frequent dosing, and how pricing would be approached for these indications.
Answer
CEO Tim Van Hauwermeiren provided a direct response, stating that the company does not anticipate any difference in dosing regimen or pricing for seronegative or ocular MG patients compared to the currently approved gMG population. He characterized it as a label expansion to broaden the offering to the MG community.